company

Merck Sharp & Dohme LLC

as of 2026-07-01
Monitor thisAsk about this
at a glance
27 trials sponsored · 28 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
No financials loaded for this company (may be non-US-listed — recorded as a gap, not faked).

Pipeline

28 assets
AsenapineOlanzapineRisperidoneBackground AAP TherapyBase MonotherapyComparator: DextromethorphanComparator: MK2637Customized Adherence Enhancement for Schizophrenia (CAE-S)ElpipodectMK-4334MK-5720MK-8189MK-8435 (Org 25935) 12-16 mgMK-8435 (Org 25935) 4-8 mgMK-8998MK0249MK0557MK2637MK5757Merck L-830982MoxifloxacinNicotine patchOrg 34517PreladenantSCH 900435 (Org 25935)SCH 900460SCH 900636Simvastatin

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
asset
Asenapine
small molecule
drug
Olanzapine
small molecule
drug
Risperidone
small molecule
drug
Background AAP Therapy
small molecule
drug
Base Monotherapy
small molecule
drug
Comparator: Dextromethorphan
small molecule
drug
Comparator: MK2637
small molecule
drug
Customized Adherence Enhancement for Schizophrenia (CAE-S)
BEHAVIORAL
drug